George Scangos - Agilent Technologies Independent Director
| A Stock | USD 134.18 1.10 0.81% |
Director
Dr. George A. Scangos, Ph.D., is Independent Director of the Company. Dr. Scangos has served as Chief Executive Officer and a director of Vir Biotechnology, Inc. since January 2017. From July 2010 to January 2017, Dr. Scangos served as the Chief Executive Officer and a director of Biogen Inc., a biopharmaceutical company. From 1996 to July 2010, Dr. Scangos served as the President and Chief Executive Officer of Exelixis, Inc., a drug discovery and development company. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayers biological products. Before joining Bayer in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University for six years since 2014.
| Age | 72 |
| Tenure | 11 years |
| Address | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 |
| Phone | 800 227 9770 |
| Web | https://www.agilent.com |
George Scangos Latest Insider Activity
Tracking and analyzing the buying and selling activities of George Scangos against Agilent Technologies stock is an integral part of due diligence when investing in Agilent Technologies. George Scangos insider activity provides valuable insight into whether Agilent Technologies is net buyers or sellers over its current business cycle. Note, Agilent Technologies insiders must abide by specific rules, including filing SEC forms every time they buy or sell Agilent Technologies'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
George Scangos six days ago Disposition of 10964 shares by George Scangos of Vir Biotechnology at 9.8117 subject to Rule 16b-3 | ||
George Scangos over three months ago Acquisition by George Scangos of 598270 shares of Vir Biotechnology subject to Rule 16b-3 | ||
George Scangos over three months ago Disposition of 10028 shares by George Scangos of Vir Biotechnology at 10.0456 subject to Rule 16b-3 |
Agilent Technologies Management Efficiency
The company has return on total asset of 0.0854 % which means that for every 100 dollars spent on assets, it generated a profit of $0.0854. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2195 %, implying that it made 0.2195 on every $100 invested by shareholders. Agilent Technologies' management efficiency ratios could be used to measure how well Agilent Technologies manages its routine affairs as well as how well it operates its assets and liabilities. At present, Agilent Technologies' Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Capital Employed is expected to grow to 0.14, whereas Return On Assets are forecasted to decline to 0.05. At present, Agilent Technologies' Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 650.8 M, whereas Total Assets are forecasted to decline to about 9.4 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| George Massaro | Charles River Laboratories | 73 | |
| Richard Wallman | Charles River Laboratories | 69 | |
| Michael Berendt | Waters | 71 | |
| R Keith | Thermo Fisher Scientific | 52 | |
| Elisha Finney | Mettler Toledo International | 59 | |
| Judy Lewent | Thermo Fisher Scientific | 71 | |
| Nancy Andrews | Charles River Laboratories | 63 | |
| John Schwieters | Danaher | 81 | |
| JeanPaul Mangeolle | Charles River Laboratories | 57 | |
| Laurie Glimcher | Waters | 66 | |
| Scott Sperling | Thermo Fisher Scientific | 63 | |
| Christopher Kuebler | Waters | 66 | |
| Francis deSouza | Illumina | 53 | |
| Thomas Salice | Mettler Toledo International | 61 | |
| Richard Francis | Mettler Toledo International | 52 | |
| Dion Weisler | Thermo Fisher Scientific | 53 | |
| Caspar Tudor | Waters | N/A | |
| Richard Reese | Charles River Laboratories | 75 | |
| George Milne | Charles River Laboratories | 77 | |
| Lars Sorensen | Thermo Fisher Scientific | 67 | |
| Elaine Ullian | Thermo Fisher Scientific | 70 | |
Management Performance
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0854 |
Agilent Technologies Leadership Team
Elected by the shareholders, the Agilent Technologies' board of directors comprises two types of representatives: Agilent Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agilent. The board's role is to monitor Agilent Technologies' management team and ensure that shareholders' interests are well served. Agilent Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agilent Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Philip Binns, Senior Group | ||
| Padraig McDonnell, Senior Vice President and Presidentident - Agilent CrossLab Group | ||
| Daniel Podolsky, Independent Director | ||
| Hans Bishop, Independent Director | ||
| George Scangos, Independent Director | ||
| Sue Rataj, Independent Director | ||
| Parmeet Ahuja, Vice Relations | ||
| Jacob Thaysen, Senior Vice President, Agilent, President - Life Sciences and Applied Markets Group | ||
| Darlene Solomon, CTO VP | ||
| Samraat Raha, Senior Vice President, Agilent, President - Diagnostics and Genomics Group | ||
| Paul Clark, Independent Director | ||
| Mala Anand, Independent Director | ||
| Jenipher Dalton, Chief VP | ||
| Robert McMahon, Chief Financial Officer, Senior Vice President | ||
| John Kohl, Senior Officer | ||
| Chris Swenson, VP Officer | ||
| Mikael Dolsten, Independent Director | ||
| Allison Ballmer, Vice President - Strategy and Corporate Development | ||
| Michael McMullen, CEO and President Director and Member of Executive Committee | ||
| Rodney Gonsalves, Chief Accounting Officer, Vice President, Corporate Controllership | ||
| Henrik AncherJensen, Senior Vice President, Agilent and President - Order Fulfillment | ||
| Dow Wilson, Independent Director | ||
| Diana Chiu, Interim VP | ||
| Heidi Kunz, Independent Director | ||
| Angelica III, Senior President | ||
| Otis Brawley, Independent Director | ||
| Bret DiMarco, Chief VP | ||
| Simon May, SVP Group | ||
| Frederick Schwarz, Chief SVP | ||
| Jonah Kirkwood, Senior President | ||
| Dominique Grau, Senior Vice President of Human Resources and Global Communications | ||
| Susan Rataj, Independent Director | ||
| Robert CMA, Senior CFO | ||
| Michael Tang, Senior Vice President General Counsel, Secretary | ||
| Tadataka Yamada, Independent Director | ||
| Katharine Knobil, Chief Medical Officer. | ||
| Boon Koh, Non-Executive Independent Chairman of the Board | ||
| Yvonne Mackie, MD Europe |
Agilent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agilent Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0854 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 40.65 B | ||||
| Shares Outstanding | 285.29 M | ||||
| Shares Owned By Insiders | 0.43 % | ||||
| Shares Owned By Institutions | 91.48 % | ||||
| Number Of Shares Shorted | 3.25 M | ||||
| Price To Earning | 37.55 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agilent Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Agilent Stock refer to our How to Trade Agilent Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agilent Technologies. If investors know Agilent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agilent Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.25) | Dividend Share 0.944 | Earnings Share 4.43 | Revenue Per Share | Quarterly Revenue Growth 0.008 |
The market value of Agilent Technologies is measured differently than its book value, which is the value of Agilent that is recorded on the company's balance sheet. Investors also form their own opinion of Agilent Technologies' value that differs from its market value or its book value, called intrinsic value, which is Agilent Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agilent Technologies' market value can be influenced by many factors that don't directly affect Agilent Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agilent Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Agilent Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agilent Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.